Clinical Trial Update: A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 3]

View source ↗

Summary

A Phase III trial evaluating SHR-A1811 with chemotherapy and Adebrelimab in untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Adebrelimab (adebrelimab)
• SHR-A1811

Snippet

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Conditions: Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 3 | Status: RECRUITING